Has the Scrutiny Reached a Fever Pitch? Taking the Temperature of Private Equity in Healthcare: A Podcast Episode with Managing Partner Jeny Maier

September 4, 2026

30th Annual IBA Competition Conference

Axinn is proud to sponsor the International Bar Association’s Annual Competition Conference, being held September 4-5 in Florence, Italy.

Speaking Engagement

Antitrust

August 7, 2026

What Happens in Vegas Stays in Vegas: Third Circuit Parts Ways with Ninth Circuit and Reinstates Atlantic City Algorithmic-Pricing Claim

The Third Circuit (Cornish-Adebiyi v. Caesars Entertainment, Inc.) has now joined the Ninth Circuit (Gibson v. Cendyn Group, LLC) in...

Axinn Viewpoints

Antitrust

August 3, 2026

What Should Directors Be Asking? Antitrust in the Boardroom

Competition law isn't just for antitrust lawyers anymore—it's increasingly a boardroom issue. What questions should directors be asking to ensure their companies are identifying and managing competition risk before it becomes a crisis?

Podcast

Antitrust

July 31, 2026

Axinn Represents Modular in $4 Billion Acquisition by Qualcomm

Axinn LLP represented Modular Inc., an AI software infrastructure company, as antitrust counsel in its $4 billion acquisition by Qualcomm Incorporated (NASDAQ: QCOM). The acquisition strengthens Qualcomm Technologies’ AI software capabilities by combining Modular’s AI-native software infrastructure platform with Qualcomm’s high-performance, energy-efficient compute solutions to accelerate generative and agentic AI across edge, cloud, and data center environments. The transaction closed on July 29, 2026.

Deals & Cases

Antitrust

July 31, 2026

Will New DOJ Timing Agreement Deliver Faster Merger Clearances?

Since the advent of the second Trump administration, leaders of the U.S. antitrust agencies have emphasized this administration’s more...

Axinn Viewpoints

Antitrust

July 30, 2026

Why U.S. Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector

Axinn managing partner Jeny Maier, counsel Monica Smith, and associate Leandra Ipiña co-authored a chapter in Global Competition Review’s Americas Antitrust Review 2027 titled “Why U.S. Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector.”

Byline Articles

Antitrust

July 29, 2026

Women Leaders in Life Sciences Law

Axinn attorneys Denise Plunkett and Rebecca Clegg will speak on panels during the American Conference Institute's 13th Annual Summit for Women Leaders in Life Sciences Law, July 29–30 in Boston, MA.

Speaking Engagement

Litigation & Trials

July 28, 2026

American Bar Association: Inside Antitrust Enforcement—Former Government Perspectives

Axinn Partners Leslie Overton, Dan Matheson, James "Jimmy" Moore, and Associate Anna Van de Stouwe will serve as the roundtable panel during the American Bar Association's Webinar titled "Inside Antitrust Enforcement—Former Government Perspectives."

Webinar

Antitrust

July 28, 2026

What's the Skinny on SCOTUS' Skinny Label Decision?

The Supreme Court’s recent Hikma v. Amarin decision has renewed attention on induced infringement of method-of-use claims in Hatch-Waxman cases. This CLE will contextualize the decision and explore the extent to which it represents a mere refocusing of the law rather than a dramatic shift.

Webinar

Intellectual Property

July 27, 2026

National Bar Association Corporate Counsel Leadership Summit

Panel: What's Going On: Making Sense of AI’s Impact on the Legal Profession and Client Strategies.

Speaking Engagement

Antitrust

July 22, 2026

FTC Prescribes Lower Out-of-Pocket Insulin Costs in Settlement with Caremark

On July 14, 2026, the Federal Trade Commission and Caremark Rx LLC and Zinc Health Services LLC (collectively “Caremark”) reached a...

Axinn Viewpoints

Antitrust

July 20, 2026

The FTC’s Record $12 Million HSR Penalty: Deal Structuring, Avoidance, and the Line Between Them

Parties structure transactions with the HSR Act in mind all the time, and nothing in the Act requires them to make a deal reportable. What parties cannot do, in the FTC's view, is disguise a reportable transaction as a non-reportable one. The FTC's latest enforcement action – and the largest penalty in the HSR Act's history – shows where the agency draws that line and what it now charges for crossing it.

Axinn Viewpoints

Antitrust

Has the Scrutiny Reached a Fever Pitch? Taking the Temperature of Private Equity in Healthcare: A Podcast Episode with Managing Partner Jeny Maier

Related Services

News & Insights

News & Insights